FUNDAMENTALS · Fundamentals · TW Healthcare

PharmaEngine (4162) Fundamentals 2026 — P/E 23.3x, Revenue Analysis | SniperIQ

PharmaEngine (4162) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$9.8B, trading at NT$68.40 on the TWO. This SniperIQ fundamentals page covers PharmaEngine's valuation (P/E 23.3x, P/B 1.9x), profitability (net margin 43.8%), revenue (NT$911M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$9.8B
P/E (TTM)23.3x
Net Margin43.8%
Revenue (FY25)NT$911M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is PharmaEngine's market cap?

PharmaEngine (4162) has a market capitalization of approximately NT$9.8B, trading at NT$68.40 on the TWO. Market cap moves with the live share price.

What is PharmaEngine's P/E ratio?

PharmaEngine's trailing twelve-month P/E ratio is 23.3x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is PharmaEngine?

PharmaEngine runs a net profit margin of 43.8%, a gross margin of 94.1%, and an operating margin of 48.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does PharmaEngine generate?

PharmaEngine reported revenue of NT$911M for fiscal year 2025, with net income of NT

88M and earnings per share (EPS) of 2.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does PharmaEngine pay a dividend?

PharmaEngine offers a trailing dividend yield of about 8.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is PharmaEngine financially healthy?

PharmaEngine carries a debt-to-equity ratio of 0.01x and a current ratio of 29.16x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is PharmaEngine a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PharmaEngine (4162) the key facts are: market cap NT$9.8B, P/E 23.3x, revenue NT$911M, 52-week range 53-81.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track PharmaEngine's full fundamentals live

Get PharmaEngine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.